C4 Therapeutics, Inc. (CCCC) Reports Early Biomarker and Safety Updates in Cemsidomide Combos

C4 Therapeutics presented biomarker data showing T—cell activation with cemsidomide and said the 75 µg dose with elranatamab was declared safe, enabling expansion at 75 µg and escalation to 100 µg; full Phase 1b cohort data are expected in mid—2027.Material DetailsContext by AI AnalystThis is an ea…